Evidence map›Paper›PMID 24763400›Full record

Trial reportHaematologica2014

Risk adapted high-dose and dose-dense therapies modulate the impact of biological classification in diffuse large B-cell lymphoma prognosis.

Santiago Montes-Moreno, Ana Batlle, Sonia González de Villambrosía, Beatriz Sánchez-Espiridión, Laura Cereceda, Eva González-Barca, Noelia Purroy, Emilia Pardal, Alejandro Martín, Carlos Grande and 14 more

Abstract readClinical TrialLetter
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Haematologica, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Santiago Montes-MorenoPathology Department, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain GELTAMO Group, Spanish Society of Hematology, Santander, Spain smontes@humv.es.
Ana BatlleDepartment of Hematology, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
Sonia González de VillambrosíaGELTAMO Group, Spanish Society of Hematology, Santander, Spain Department of Hematology, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
Beatriz Sánchez-EspiridiónGrupo de Genómica del Cáncer, IDIVAL, Santander, Spain.
Laura CerecedaGrupo de Genómica del Cáncer, IDIVAL, Santander, Spain.
Eva González-BarcaGELTAMO Group, Spanish Society of Hematology, Santander, Spain Servicio de Hematología Clínica, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain.
Noelia PurroyPETHEMA, Programa Español de tratamientos en Hematología, L'Hospitalet de Llobregat, Barcelona, Spain Department of Hematology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Emilia PardalGELTAMO Group, Spanish Society of Hematology, Santander, Spain Department of Hematology, Hospital Virgen del PuertoPlasencia, Salamanca, Spain.
Alejandro MartínGELTAMO Group, Spanish Society of Hematology, Santander, Spain Department of Hematology, Hospital Universitario de Salamanca/IBSAL, Salamanca, Spain.
Carlos GrandeGELTAMO Group, Spanish Society of Hematology, Santander, Spain Department of Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain.
Francisco MazorraPathology Department, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.
Andrés InsunzaGELTAMO Group, Spanish Society of Hematology, Santander, Spain.
Cristina QueroGOTEL (Grupo Oncológico para el Tratamiento de las Enfermedades Linfoides), L'Hospitalet de Llobregat, Barcelona, Spain Oncology Department, Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain.
David AguiarGOTEL (Grupo Oncológico para el Tratamiento de las Enfermedades Linfoides), L'Hospitalet de Llobregat, Barcelona, Spain Oncology Department, Hospital Universitario de Gran Canaria, Dr Negrín, Gran Canaria, Spain.
Miguel Angel CruzGOTEL (Grupo Oncológico para el Tratamiento de las Enfermedades Linfoides), L'Hospitalet de Llobregat, Barcelona, Spain Oncology Department, Hospital Virgen de la Salud, Toledo, Spain.
Antonio RuedaGOTEL (Grupo Oncológico para el Tratamiento de las Enfermedades Linfoides), L'Hospitalet de Llobregat, Barcelona, Spain Oncology Department, Hospital Costa del Sol, Marbella, Spain.
Marta LlanosGOTEL (Grupo Oncológico para el Tratamiento de las Enfermedades Linfoides), L'Hospitalet de Llobregat, Barcelona, Spain Oncology Department, Hospital Universitario de Canarias, La Laguna, Spain.
José Gómez CodinaGOTEL (Grupo Oncológico para el Tratamiento de las Enfermedades Linfoides), L'Hospitalet de Llobregat, Barcelona, Spain Oncology Department, Hospital La Fe, Valencia, Spain.
Francisco Ramón García ArroyoGOTEL (Grupo Oncológico para el Tratamiento de las Enfermedades Linfoides), L'Hospitalet de Llobregat, Barcelona, Spain Oncology Department, Hospital de Pontevedra, Madrid, Spain.
Dolores CaballeroGELTAMO Group, Spanish Society of Hematology, Santander, Spain Department of Hematology, Hospital Universitario de Salamanca/IBSAL, Salamanca, Spain.
Eulogio CondeGELTAMO Group, Spanish Society of Hematology, Santander, Spain Department of Hematology, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
Andrés LópezPETHEMA, Programa Español de tratamientos en Hematología, L'Hospitalet de Llobregat, Barcelona, Spain Department of Hematology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Mariano ProvencioGOTEL (Grupo Oncológico para el Tratamiento de las Enfermedades Linfoides), L'Hospitalet de Llobregat, Barcelona, Spain Oncology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain.
Miguel PirisPathology Department, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Stem Cell TransplantationAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDose-Response Relationship, DrugDoxorubicinFemaleFollow-Up StudiesHumansLymphoma, Large B-Cell, DiffuseMaleMiddle AgedPrednisoneCyclophosphamideDoxorubicinPrednisoneVincristinebiological classificationdiffuse large B-cell lymphomadose-dense therapieshigh-dose

Identifiers

PMID24763400
PMCPMC4116846

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.